These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22748800)

  • 41. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders.
    Fukata M; Vamadevan AS; Abreu MT
    Semin Immunol; 2009 Aug; 21(4):242-53. PubMed ID: 19748439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toll-like receptors: potential targets for lupus treatment.
    Wu YW; Tang W; Zuo JP
    Acta Pharmacol Sin; 2015 Dec; 36(12):1395-407. PubMed ID: 26592511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
    Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
    IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nucleic acid recognizing Toll-like receptors and autoimmunity.
    von Landenberg P; Bauer S
    Curr Opin Immunol; 2007 Dec; 19(6):606-10. PubMed ID: 18060756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toll-like receptors: emerging concepts in kidney disease.
    Anders HJ; Schlöndorff D
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):177-83. PubMed ID: 17420659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toll-like receptors: a novel target for therapeutic intervention in intestinal and hepatic ischemia-reperfusion injury?
    Vasileiou I; Kostopanagiotou G; Katsargyris A; Klonaris C; Perrea D; Theocharis S
    Expert Opin Ther Targets; 2010 Aug; 14(8):839-53. PubMed ID: 20568914
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toll-like receptors in ischemia-reperfusion injury.
    Arumugam TV; Okun E; Tang SC; Thundyil J; Taylor SM; Woodruff TM
    Shock; 2009 Jul; 32(1):4-16. PubMed ID: 19008778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insights into the role of Toll-like receptors in modulation of T cell responses.
    Kulkarni R; Behboudi S; Sharif S
    Cell Tissue Res; 2011 Jan; 343(1):141-52. PubMed ID: 20680345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases.
    Lin E; Freedman JE; Beaulieu LM
    Cardiovasc Ther; 2009; 27(2):117-23. PubMed ID: 19426249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interleukin receptor-associated kinase-4 deficiency impairs Toll-like receptor-dependent innate antiviral immune responses.
    McDonald DR; Brown D; Bonilla FA; Geha RS
    J Allergy Clin Immunol; 2006 Dec; 118(6):1357-62. PubMed ID: 17157666
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Innate immunity: structure and function of TLRs].
    Delneste Y; Beauvillain C; Jeannin P
    Med Sci (Paris); 2007 Jan; 23(1):67-73. PubMed ID: 17212934
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent progress in the development of Toll-like receptor (TLR) antagonists.
    Patra MC; Choi S
    Expert Opin Ther Pat; 2016 Jun; 26(6):719-30. PubMed ID: 27136061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TLR Agonists as Adjuvants for Cancer Vaccines.
    Li JK; Balic JJ; Yu L; Jenkins B
    Adv Exp Med Biol; 2017; 1024():195-212. PubMed ID: 28921471
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of toll-like receptors in inflammatory bowel disease.
    Kordjazy N; Haj-Mirzaian A; Haj-Mirzaian A; Rohani MM; Gelfand EW; Rezaei N; Abdolghaffari AH
    Pharmacol Res; 2018 Mar; 129():204-215. PubMed ID: 29155256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Importance of Nucleic Acid Recognition in Inflammation and Autoimmunity.
    Barrat FJ; Elkon KB; Fitzgerald KA
    Annu Rev Med; 2016; 67():323-36. PubMed ID: 26526766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma.
    Aryan Z; Holgate ST; Radzioch D; Rezaei N
    Int Arch Allergy Immunol; 2014; 164(1):46-63. PubMed ID: 24853609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toll-like receptors in systemic lupus erythematosus: potential targets for therapeutic intervention.
    Horton CG; Farris AD
    Curr Allergy Asthma Rep; 2012 Feb; 12(1):1-7. PubMed ID: 22086298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Melatonin, a toll-like receptor inhibitor: Current status and future perspectives.
    Tamtaji OR; Mobini M; Reiter RJ; Azami A; Gholami MS; Asemi Z
    J Cell Physiol; 2019 Jun; 234(6):7788-7795. PubMed ID: 30387141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.
    Federico S; Pozzetti L; Papa A; Carullo G; Gemma S; Butini S; Campiani G; Relitti N
    J Med Chem; 2020 Nov; 63(22):13466-13513. PubMed ID: 32845153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Toll-like receptor agonists in cancer therapy.
    Adams S
    Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.